Vertex Pharmaceuticals Inc (VRTX: NASDAQ)
$129.36 n/a | n/a%
11/30/15 - 03:59 PM ET
|REVENUE (Trailing 12 Quarters)|
|EARNINGS PER SHARE (Trailing 12 Quarters)|
|DIVIDENDS (Trailing 12 Quarters)|
Portfolios with VRTX
- Portfolio NameUser Type
- ProAdage Capital
- ContributorMonster Momentum Stocks To ...
- ContributorBreakout Stocks Of The Week...
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
Latest VRTX Headlines from TheStreet
- Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express 11.30.15 | 08:11 pm
- Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending 09.22.15 | 07:09 am
- Biotech Stocks Recover From Early-Morning Flash Crash 08.24.15 | 12:08 pm
- 50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs 08.14.15 | 09:08 pm
- 3 Stocks Boosting The Drugs Industry Higher 08.04.15 | 01:08 pm
- 3 Drugs Stocks Pushing Industry Growth 07.30.15 | 01:07 pm
- Vertex Pharmaceuticals (VRTX) Earnings Report: Q2 2015 Conference Call Transcript 07.30.15 | 10:07 am
- Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock 07.29.15 | 04:07 pm
- Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today 07.15.15 | 10:07 am
- Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock 07.02.15 | 12:07 pm
Press Releases for VRTX
- Vertex Reports Second Quarter 2015 Financial Results - Business Wire 07.29.15 | 04:07 pm
- Vertex To Announce Second Quarter 2015 Financial Results On July 29 - Business Wire 07.14.15 | 09:07 am
- ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation - Business Wire 07.02.15 | 01:07 pm
- Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors - Business Wire 06.18.15 | 04:06 pm
- Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference - Business Wire 06.11.15 | 09:06 am
- Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases - Business Wire 06.04.15 | 04:06 pm
- Vertex To Present At The Goldman Sachs Healthcare Conference On June 11 - Business Wire 06.03.15 | 04:06 pm
- New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 05.17.15 | 01:05 pm
- Vertex To Present At The UBS Healthcare Conference On May 19 - Business Wire 05.13.15 | 04:05 pm
- Food And Drug Administration Advisory Panel Voted 12 To 1 To Recommend Approval Of ORKAMBI™ (lumacaftor/ivacaftor) To Treat People With Cystic Fibrosis Ages 12 And Older Who Have Two Copies Of The F508del Mutation - Business Wire 05.12.15 | 04:05 pm
Partner Headlines for VRTX
- Vertex approval in Europe to bring gradual uptake, says Piper Jaffray - The Fly 11.20.15 | 10:11 am
- Vertex making progress outside of cystic fibrosis, says UBS - The Fly 11.10.15 | 07:11 am
- Piper sees Biotech fundamentals as 'strong' despite pricing chatter - The Fly 11.10.15 | 06:11 am
- Once a Takeover Candidate, Vertex Is Now Looking for Deals - Bloomberg 11.04.15 | 05:11 am
- Vertex upgraded to Buy from Neutral at H.C. Wainwright - The Fly 10.30.15 | 07:10 am
- Vertex price target raised to $180 from $163 at Piper Jaffray - The Fly 10.29.15 | 05:10 am
- Vertex remains top large-cap pick into Q3 results at Piper Jaffray - The Fly 10.20.15 | 06:10 am
- Vertex checks positive, says RBC Capital - The Fly 10.12.15 | 08:10 am
- Vertex upgraded to Overweight from Equal Weight at Morgan Stanley - The Fly 10.02.15 | 07:10 am
- The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene - Zacks 10.01.15 | 09:10 am